Compare ALGN & ELAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALGN | ELAN |
|---|---|---|
| Founded | 1997 | 1954 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3B | 10.3B |
| IPO Year | N/A | 2018 |
| Metric | ALGN | ELAN |
|---|---|---|
| Price | $167.81 | $24.77 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 10 |
| Target Price | ★ $174.00 | $24.44 |
| AVG Volume (30 Days) | 808.8K | ★ 4.7M |
| Earning Date | 02-04-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 5.16 | 0.07 |
| Revenue | $3,982,622,000.00 | ★ $4,591,000,000.00 |
| Revenue This Year | $2.58 | $7.25 |
| Revenue Next Year | $3.66 | $5.69 |
| P/E Ratio | ★ $32.48 | $340.63 |
| Revenue Growth | 0.56 | ★ 3.08 |
| 52 Week Low | $122.00 | $8.02 |
| 52 Week High | $234.19 | $25.29 |
| Indicator | ALGN | ELAN |
|---|---|---|
| Relative Strength Index (RSI) | 55.73 | 63.21 |
| Support Level | $164.44 | $23.67 |
| Resistance Level | $172.36 | $25.29 |
| Average True Range (ATR) | 4.44 | 0.75 |
| MACD | -0.66 | 0.06 |
| Stochastic Oscillator | 51.58 | 81.02 |
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.